Association of Genetic Polymorphisms with Warfarin Dose Requirements in Chinese Patients

被引:20
|
作者
Liang, Yundan [1 ,2 ]
Chen, Zhiyu [3 ]
Guo, Gang [4 ]
Dong, Xuemei [5 ]
Wu, Chunting [1 ]
Li, He [1 ]
Wang, Tong [1 ]
Xu, Bingying [1 ]
机构
[1] Kunming Med Univ, Sch Forens Med, Kunming, Peoples R China
[2] Hosp Yunnan Univ Nationalities, Kunming, Peoples R China
[3] Kunming Med Univ, Yan An Hosp, Kunming, Peoples R China
[4] Chongqing City Publ Secur Bur, Mat Evidence Identificat Ctr, Chongqing, Peoples R China
[5] Lin Cang Police Bur, Inst Criminal Sci & Technol, Lin Cang, Peoples R China
基金
中国国家自然科学基金;
关键词
GAMMA-GLUTAMYL-CARBOXYLASE; K EPOXIDE REDUCTASE; ANTICOAGULANT RESPONSE; JAPANESE PATIENTS; CLINICAL FACTORS; CYP2C9; POPULATION; THERAPY; PHARMACOGENETICS; PREDICTION;
D O I
10.1089/gtmb.2013.0303
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Objective: Warfarin is a commonly used anticoagulant with a narrow therapeutic range and large interindividual differences in dosing requirements. Previously, studies have identified that the interindividual variability was influenced by varieties of factors, including age, body size, vitamin K intake, interacting medications, as well as genetic variants. We aimed to investigate the effect of single-nucleotide polymorphisms (SNPs) on the interindividual variability of warfarin dose requirements in Chinese patients.Methods: The study population consisted of 300 patients with a stable maintenance dose of warfarin. We examined SNPs in eight genes involving in the biotransformation and mode of action of warfarin (i.e., CYP4F2, CYP2C19, APOE, CALU, EPHX1, PROC, CYP2C9, and GGCX) using the SNaPshot assay.Results: The mean daily warfarin dose in patients carrying CYP2C19 rs3814637CC, CYP2C9 rs1057910AA, and GGCX rs699664AA genotype was 3.39, 3.34, and 3.51mg/day, respectively, which was higher than those carrying CYP2C19 rs3814637TT, CYP2C9 rs1057910CC, and rs699664GG genotype (2.00, 0.81, and 3.09mg/day, respectively).Conclusion: These findings indicate that individuals carrying the CYP2C19 rs3814637CC or CYP2C9 rs1057910AA or GGCX rs699664AA genotype needed higher warfarin doses in the Chinese population.
引用
收藏
页码:932 / 936
页数:5
相关论文
共 50 条
  • [1] Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients
    Xu, Qingqing
    Zhang, Suli
    Wu, Chaoneng
    Xiong, Yuyu
    Niu, Jiamin
    Li, Fengzhen
    Zhu, Jinhang
    Shen, Lu
    Zhu, Bin
    Xing, Qinghe
    He, Lin
    Chen, Luan
    Li, Mo
    Li, Hua
    Ge, Junbo
    Qin, Shengying
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 78 (01) : 105 - 111
  • [2] Genetic polymorphisms are associated with variations in warfarin maintenance dose in Fan Chinese patients with venous thromboembolism
    Zhang, Wei
    Zhang, Wei-Juan
    Zhu, Jin
    Kong, Fan-Cui
    Li, Yan-Yan
    Wang, He-Yao
    Yang, Yuan-Hua
    Wang, Chen
    [J]. PHARMACOGENOMICS, 2012, 13 (03) : 309 - 321
  • [3] Influence of GGCX genotype on warfarin dose requirements in Chinese patients
    Huang, Sheng-Wen
    Xiang, Dao-Kang
    Huang, Ling
    Chen, Bao-Lin
    An, Bang-Quan
    Li, Gui-Fang
    Luo, Zhen-Yuan
    [J]. THROMBOSIS RESEARCH, 2011, 127 (02) : 131 - 134
  • [4] CYP4F2 GENETIC POLYMORPHISMS INFLUENCE WARFARIN DOSE REQUIREMENTS IN POLYMEDICATED PATIENTS INITIATING WARFARIN THERAPY
    Michaud, V.
    Frappier, M.
    Champagne, M.
    Brouillette, D.
    Roy, D.
    Verret, L.
    Noel, N.
    Taillon, I.
    O'Hara, G.
    Gossard, D.
    Goodman, K.
    Vanier, M.
    Phillips, M.
    Ajami, A.
    Turgeon, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S17 - S17
  • [5] Impact of GGCX polymorphisms on warfarin dose requirements in atrial fibrillation patients
    Jiang, Nian-Xin
    Xu, Ying-Hui
    Xia, Jing-Wen
    Jiang, Bing
    Li, Yan-Song
    [J]. TURKISH JOURNAL OF MEDICAL SCIENCES, 2017, 47 (04) : 1239 - 1246
  • [6] Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients
    Shahin, Mohamed Hossam A.
    Khalifa, Sherief I.
    Gong, Yan
    Hammad, Lamiaa N.
    Sallam, Mohamed T. H.
    El Shafey, Mostafa
    Ali, Shawky S.
    Mohamed, Mohamed-Eslam F.
    Langaee, Taimour
    Johnson, Julie A.
    [J]. PHARMACOGENETICS AND GENOMICS, 2011, 21 (03): : 130 - 135
  • [7] Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
    Payman Shahabi
    Félix Lamothe
    Stéphanie Dumas
    Étienne Rouleau-Mailloux
    Yassamin Feroz Zada
    Sylvie Provost
    Geraldine Asselin
    Ian Mongrain
    Diane Valois
    Marie-Josée Gaulin Marion
    Louis-Philippe Lemieux Perreault
    Sylvie Perreault
    Marie-Pierre Dubé
    [J]. The Pharmacogenomics Journal, 2019, 19 : 147 - 156
  • [8] Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
    Shahabi, Payman
    Lamothe, Felix
    Dumas, Stephanie
    Rouleau-Mailloux, Etienne
    Zada, Yassamin Feroz
    Provost, Sylvie
    Asselin, Geraldine
    Mongrain, Ian
    Valois, Diane
    Marion, Marie-Josee Gaulin
    Perreault, Louis-Philippe Lemieux
    Perreault, Sylvie
    Dube, Marie-Pierre
    [J]. PHARMACOGENOMICS JOURNAL, 2019, 19 (02): : 147 - 156
  • [9] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
    Taisei Mushiroda
    Yozo Ohnishi
    Susumu Saito
    Atsushi Takahashi
    Yuka Kikuchi
    Shigeru Saito
    Hideki Shimomura
    Yasuhiko Wanibuchi
    Takao Suzuki
    Naoyuki Kamatani
    Yusuke Nakamura
    [J]. Journal of Human Genetics, 2006, 51 : 249 - 253
  • [10] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
    Mushiroda, T
    Ohnishi, Y
    Saito, S
    Takahashi, A
    Kikuchi, Y
    Saito, S
    Shimomura, H
    Wanibuchi, Y
    Suzuki, T
    Kamatani, N
    Nakamura, Y
    [J]. JOURNAL OF HUMAN GENETICS, 2006, 51 (03) : 249 - 253